Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Current ratio

Current ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
23.8×-6.3×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10.2×+7.0×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
5.5×-0.4×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
10.8×+2.3×

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.56B-45.9%
Enterprise value$1.36B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×

Where this comes from

Calculated from MoonLake Immunotherapeutics’s reported figures.

total current assets/total current liabilities=8.6×

Based on the most recent quarter.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's current ratio?
MoonLake Immunotherapeutics (MLTX) reported current ratio of 8.6× in Q1 2026.
How has MoonLake Immunotherapeutics's current ratio changed year-over-year?
MoonLake Immunotherapeutics's current ratio decreased by 59.3% year-over-year, from 21.1× to 8.6×.
What is the long-term trend for MoonLake Immunotherapeutics's current ratio?
Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's current ratio has grown at a -6.4% compound annual growth rate (CAGR), from 12.9× to 9.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.